Tata Motors Q4 FY26 Results: CV Business Revenue Rises 22%, PAT Jumps 70%

Tata Motors delivered a strong quarter for its standalone commercial vehicle (CV) business in Q4 FY26. Revenue for the March quarter went up 22% year-on-year (YoY) to ₹24,452 crore, and EBITDA rose 35% YoY to ₹3,400 crore. EBITDA margin improved by 130 basis points to 13.9%.

Tata Motors CV share price closed at ₹384.25 on the National Stock Exchange, down by 0.72%.

Tata Motors Financial Performance

Profit before tax (before exceptional items) stood at ₹2,972 crore in Q4 FY26, up 58% YoY. Profit after tax for the quarter rose 70% YoY to around ₹2,400 crore.

For the full FY26, standalone revenue increased 11% YoY to ₹77,399 crore. EBITDA grew 22% YoY to ₹10,200 crore, while EBITDA margin improved to 13.2% from 12.0% a year ago. Profit before tax (before exceptional items) came in at ₹8,682 crore, up 46% YoY.

The company said full-year profit after tax stood at ₹3,400 crore, down 23% YoY due to exceptional items worth around ₹3,700 crore related to mark-to-market losses on listed investments in Tata Capital, costs linked to the new labour code and demerger-related expenses.

Tata Motors generated free cash flow of ₹9,186 crore during FY26, up ₹2,179 crore from the previous year. Net cash for the domestic business stood at ₹7,500 crore as of March 31, 2026. The company added that its disciplined capital allocation strategy helped it achieve a return on capital employed (ROCE) of 72% during FY26 compared with 61% in FY25.

On the consolidated front, Q4 FY26 revenue stood at ₹26,100 crore, up 19% YoY. EBITDA margin improved by 150 basis points to 13.1%, while profit after tax rose 35% YoY to ₹1,800 crore. The company stayed net cash-positive at ₹13,700 crore.

Commercial vehicle wholesales during the quarter stood at 132,000 units, up 25% YoY. Full-year wholesales increased 14% YoY to 428,000 units, with domestic and export volumes rising 12% and 54% respectively.

The board has recommended a final dividend of ₹4 per equity share for FY26, subject to approvals.

Also Read - GlaxoSmithKline Pharmaceuticals Q4 FY26 Results: PAT At ₹275 Crore, Board Recommends ₹57 Dividend

Source:

Company Press Release